Generated by All in One SEO v5.0.1.1, this is an llms.txt file, used by LLMs to index the site. # Witfire Elite Pharma News Pharma business news, market intelligence, and CEO-level case studies ## Posts - [RENGEVITY-201 Trial: Pegrizeprument Takes On Tacrolimus](https://thewitfire.in/rengevity-201-trial-pegrizeprument-takes-on-tacrolimus/) - RENGEVITY-201 trial begins Phase 2 testing of pegrizeprument against tacrolimus in kidney transplantation. We examine its design, evidence gaps and risks. - [Alevia-B: PascualLab's Pain and Mobility Push](https://thewitfire.in/alevia-b-pascuallabs-pain-and-mobility-push/) - Alevia-B combines paracetamol with vitamins B1, B6 and B12. Its 2025 Philippine FDA record predates PascualLab's current pain and mobility campaign in 2026. - [Philippine FDA CPR Renewal Rule: Advisory 2026-1007](https://thewitfire.in/philippine-fda-cpr-renewal-rule-advisory-2026-1007/) - Philippine FDA CPR renewal guidance confirms when an expired medical-device CPR remains valid during review and which records importers may present. - [PULSE-LHD Trial Enrols First U.S. Patients](https://thewitfire.in/pulse-lhd-trial-enrols-first-u-s-patients/) - Pulnovo reports two U.S. procedures in the PULSE-LHD trial. The estimated 750-participant IDE study uses a sham control; no results are posted. - [HARBOR-AF Trial: First European Patient Dosed](https://thewitfire.in/harbor-af-trial-first-european-patient-dosed/) - HARBOR-AF trial begins in Europe as XYRA doses the first patient. Read its budiodarone dosing design, AF burden endpoints, safety risks and major evidence gaps. - [Ravulizumab ARTEMIS: 555 Patients, Six Terminations, and a Mechanism That Did Not Travel](https://thewitfire.in/ravulizumab-artemis-trial-terminated-ultomiris-expansion/) - Ravulizumab ARTEMIS ended at 555 of 736 patients with no reason recorded. Six expansion trials, 1,316 patients, zero new indications. Every figure computed. - [OX40 Atopic Dermatitis: A Drug Class Ended in 175 Days and 8,185 Patients](https://thewitfire.in/ox40-atopic-dermatitis-class-collapse-registry-analysis/) - OX40 atopic dermatitis development is over. Registry data puts 8,185 patients in terminated or winding-down trials, one Phase 3 still listed as recruiting. - [Teva Q2 2026 Results: What the Numbers Actually Say](https://thewitfire.in/teva-q2-2026-results-what-the-numbers-actually-say/) - Teva Q2 2026 results, decomposed. Brands refilled 101.6% of the generics hole. Most of the EBITDA fall is one charge. The guidance raise adds no profit. - [J&J Talc Settlement: $5.5 Billion, 76,000 Claims and the 95% Condition](https://thewitfire.in/jj-talc-settlement-5-5-billion-76000-claims/) - The J&J talc settlement commits $5.5 billion across roughly 76,000 claims. Here is what each figure means, why J&J settled after winning, and what it excludes. - [FDA Issues CRL to Sobi for NASP in Uncontrolled Gout](https://thewitfire.in/fda-issues-crl-to-sobi-for-nasp-in-uncontrolled-gout/) - FDA Issues CRL to Sobi for NASP in Uncontrolled Gout, but the letter did not attack the clinical case. It attacked manufacturing control, CMC readiness and contract manufacturing deficiencies. - [Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell](https://thewitfire.in/viridian-lumvoa-fda-approval-tepezza-challenge/) - Viridian’s Lumvoa approval breaks Tepezza’s TED monopoly. Inside the label, Phase 3 data, safety risks, payer hurdles and subcutaneous pipeline. - [Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3](https://thewitfire.in/tanabes-uplizna-defense-obexelimab-had-already-won-phase-3/) - 4SigHT is formally a long-term observational study. Strategically, its timing points to something larger: Tanabe is building a Japanese real-world evidence moat before Bristol Myers Squibb brings a self-administered rival into the market. - [AlzeCure ACD856 QuantumCell Deal: $2.2B Risk Transfer in Alzheimer’s](https://thewitfire.in/alzecure-acd856-quantumcell-deal-2-2b-risk-transfer-in-alzheimers/) - AlzeCure licensed NeuroRestore ACD856 to QuantumCell in a deal worth over $2.2B. The real story is not proof, but Alzheimer’s risk transfer. - [Eplontersen CARDIO-TTRansform Miss: ATTR-CM Analysis](https://thewitfire.in/eplontersen-cardio-ttransform-miss-attr-cm-analysis/) - Eplontersen missed the CARDIO-TTRansform primary endpoint in ATTR-CM. Inside the stabilizer effect, monotherapy signal, market impact and trial-design risk. - [The Stabilizer Ceiling: What 3 Amyloidosis Trials Reveal](https://thewitfire.in/the-stabilizer-ceiling-what-3-amyloidosis-trials-reveal/) - Three amyloidosis trials reveal the stabilizer ceiling in ATTR-CM, where add-on drugs lose signal as modern background therapy saturates outcomes. - [Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha](https://thewitfire.in/oral-pcsk9-inhibitor-approved-lipfendra-price-vs-repatha/) - Merck's LIPFENDRA is the first oral PCSK9 inhibitor, approved at $315 a month. Repatha already sells cash at $239. Full data, pricing and risk score. - [Achieve Cytisinicline CRL: Rejection That Did Not Break the Company](https://thewitfire.in/achieve-cytisinicline-crl-rejection-that-did-not-break-the-company/) - Achieve’s cytisinicline CRL cited a prior facility and incomplete labeling, not clinical failure. Why this CMC rejection looks survivable. - [Unicycive OLC CRL: The CMC Failure Behind a Biotech Selloff](https://thewitfire.in/unicycive-olc-crl-the-cmc-failure-behind-a-biotech-selloff/) - Unicycive OLC received a second FDA CRL over third-party manufacturing deficiencies. The case shows why CMC risk now drives biotech valuation. - [Novo Nordisk Eli Lilly Lawsuit: What the Case Turns On](https://thewitfire.in/novo-nordisk-eli-lilly-lawsuit-what-the-case-turns-on/) - Inside the Novo Nordisk Eli Lilly lawsuit: why Lilly's Zepbound vs Wegovy ads are accurate, why Novo still has a case, and what it means for India. - [Sun Pharma Organon Deal: Why 2027 Decides Everything](https://thewitfire.in/sun-pharma-organon-deal-why-2027-decides-everything/) - Sun Pharma's Organon deal cleared its shareholder vote on 24 July. Three separate deadlines — closing, patent expiry, generic entry — all land in 2027. - [Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib](https://thewitfire.in/revolution-medicines-built-a-4-3-billion-wall-around-daraxonrasib/) - Revolution Medicines built a $4.3B liquidity wall around daraxonrasib. Inside its Phase 3 data, Royalty Pharma terms, dilution and buyout risk. - [Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice](https://thewitfire.in/moderna-flu-vaccine-reversal-fda-refused-to-review-it-then-advisers-voted-9-0-twice/) - Moderna flu vaccine mFlusiva moved from an FDA refusal to a 9-0 panel vote. Inside the science, politics and August 5 decision. - [GSK Bought September and November 2026: The $10.6 Billion Nuvalent Autopsy](https://thewitfire.in/gsk-bought-september-and-november-2026-the-10-6-billion-nuvalent-autopsy/) - GSK’s $10.6B Nuvalent acquisition is more than an oncology deal. It is a pre-approval bet on zidesamtinib, neladalkib, and two FDA decision dates in 2026. - [FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma](https://thewitfire.in/fda-rejects-replimunes-rp1-despite-34-response-rate-in-melanoma/) - FDA rejected Replimune’s RP1 despite a 34% response rate in advanced melanoma. The rejection centered on single-arm trial design and evidence standards. - [India CRO Boom: Why India’s Next CRO Boom May Be Built on Molecules It Did Not Invent](https://thewitfire.in/india-cro-boom-why-indias-next-cro-boom-may-be-built-on-molecules-it-did-not-invent/) - Western pharma wants Chinese innovation but less China execution risk. That gap could become India’s next CRO/CDMO opportunity if Indian firms can become the trusted bridge. - [Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead](https://thewitfire.in/iran-war-pharma-shock-why-indias-api-dependence-hurts-more-than-chinas-biotech-lead/) - The Iran war and Strait of Hormuz disruption expose a deeper pharma asymmetry: India dominates finished generics, but China controls much of the upstream chemistry and is rising in biotech innovation. - [CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead](https://thewitfire.in/cagrisema-may-not-be-enough-to-restore-novo-nordisks-obesity-lead/) - CagriSema was built as Novo Nordisk’s next obesity weapon, but Lilly’s tirzepatide and retatrutide data suggest Novo’s challenge may be structural, not molecule-specific. - [India's Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US](https://thewitfire.in/indias-generic-ozempic-boom-is-a-margin-trap-and-the-price-collapse-it-started-has-now-reached-the-us/) - India's generic semaglutide flood has crashed Ozempic prices and dented Novo and Lilly alike. A Witfire data analysis on who actually profits—and who doesn't. - [Eli Lilly Retatrutide Phase 3 Results at ADA 2026](https://thewitfire.in/eli-lilly-retatrutide-phase-3-results-ada-2026/) - Eli Lilly Retatrutide Phase 3 Results at ADA 2026 showed up to 28.3% weight loss, broader obesity-related benefits and a stronger portfolio signal for Lilly’s obesity market strategy. - [FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug](https://thewitfire.in/ftx-6058-and-pociredir-fdas-prc2-risk-view-hit-a-promising-sickle-cell-drug/) - FTX-6058 and Pociredir showed strong early sickle cell data, but FDA’s PRC2 class-risk view after Tazverik’s blood-cancer signal ended Fulcrum’s program. - [IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion](https://thewitfire.in/iqvia-wegovy-pill-data-and-oral-glp-1-market-expansion/) - IQVIA’s early Wegovy pill data suggests oral GLP-1 drugs may expand the obesity market by bringing in new patients, not only switching users from injections. - [Fulcrum’s Pociredir Collapse: How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug](https://thewitfire.in/fulcrums-pociredir-collapse-how-fdas-prc2-risk-view-crushed-a-data-rich-sickle-cell-drug/) - Case Study on Fulcrum’s pociredir collapse, FDA’s PRC2 class-risk logic, Tazverik’s blood cancer signal, sickle-cell drug development, biotech valuation risk. - [Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection](https://thewitfire.in/philippines-ai-liver-cancer-breakthrough/) - A Witfire Breaking Analysis on how the Philippines’ CANDLE Study is using AI, genomic biomarkers, imaging, and clinical data to build a local liver cancer detection system for chronic hepatitis B patients. - [Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk](https://thewitfire.in/lilly-germany-investment-cut-pharma-capital-policy-risk/) - Eli Lilly is reportedly halving its planned €2.3 billion Germany investment, showing how drug-pricing policy, GLP-1 manufacturing demand, and US incentives are reshaping pharma investment flows. - [FDA’s Digital Liver Break: How AI Toxicology Could Change Drug Development Before Phase I](https://thewitfire.in/fda-digital-liver-break-how-ai-toxicology-could-change-drug-development-before-phase-i/) - FDA accepted the first in silico drug development tool under ISTAND to help predict drug-induced liver injury. A data-rich study for AI toxicology by Witfire. - [IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections](https://thewitfire.in/iqvia-signal-wegovy-pill-may-expand-the-glp-1-market-not-just-replace-injections/) - A data-rich pharma case study on how IQVIA’s early Wegovy pill signal suggests oral GLP-1 drugs may expand the obesity medicine market by reaching new patients. - [The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China](https://thewitfire.in/china-biotech-pipeline-grab-big-pharma-licensing-case-study/) - The China Biotech Pipeline Grab: China Biotech, Big Pharma, Pharma Licensing, Pfizer, Innovent, Bristol Myers Squibb, Hengrui, Eli Lilly, Haisco, Oncology. - [The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy](https://thewitfire.in/the-pharma-tariff-war-how-us-drug-pricing-pressure-is-forcing-big-pharma-to-rewrite-global-strategy/) - Pharma Tariff War, US Drug Pricing, Big Pharma, Pharma Manufacturing, India Pharma Exports, Roche, Novartis, Drug Supply Chain, Pharma Business - [How GLP-1 Became Pharma’s Most Powerful Growth Story](https://thewitfire.in/how-glp-1-became-pharmas-most-powerful-growth-story/) - How GLP-1 Became Pharma’s Most Powerful Growth Story. - [GLP-1 Market Becomes Pharma’s Biggest Business Battle](https://thewitfire.in/glp-1-market-becomes-pharmas-biggest-business-battle/) - GLP-1 drugs are reshaping diabetes, obesity, and metabolic healthcare by improving blood sugar control, reducing appetite, and creating one of pharma’s biggest growth markets. - [War Heat Reaches Pharma as Oil, Air Cargo and Cold-Chain Drugs Face Pressure](https://thewitfire.in/war-heat-reaches-pharma-as-oil-air-cargo-and-cold-chain-drugs-face-pressure/) - The Middle East conflict is now moving directly into pharma boardroom risk. Oil-market stress has intensified, with Vitol’s Bahrain chief warning that the market may still be underpricing the impact of disrupted Middle East supply, including a reported removal of nearly 14 million barrels per day from normal supply flows. Crude prices reportedly spiked as - [Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks](https://thewitfire.in/onlineeasypay-arrives-on-the-online-shopping-platform-shoponline-com/) - The stock market is now looking at the US-Israel-Iran conflict through a sharper pharma lens. This is no longer only a war story, an oil story, or a Wall Street volatility story. For pharmaceutical companies, this conflict has become a supply-chain test, a margin test, and a leadership test. Global markets turned cautious as fresh - [Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains](https://thewitfire.in/launches-surge-investors-seek-alternatives-to-the-industrys-biggest-names/) - The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain movement, and investor sentiment as oil and freight costs rise. The US-Israel-Iran war is now becoming more than a geopolitical headline for the pharmaceutical industry. For pharma CEOs, investors, exporters, logistics companies, and healthcare suppliers, the conflict is creating a new layer - [Data That Shows Why Pharma Business Is Becoming Bigger and More Serious](https://thewitfire.in/the-biggest-shifts-and-trends-driving-short-and-long-term-growth-in-the-future/) - The pharmaceutical business is no longer a small product-driven market. It is becoming one of the most strategic global industries. IQVIA has projected that global medicine spending may reach nearly USD 2.3 trillion by 2028. This growth is not only due to price increases. It is also linked with higher patient access, stronger use of ## Pages - [Home](https://thewitfire.in/) - Trending News Editorial picks Categories Investments business news Entrepreneurship Startups 2026INSIGHTS FOR THE NEW PHARMA LEADERS Witfire Elite brings focused perspectives on pharma growth, innovation, manufacturing, startups, and executive strategy. Read Around The World Podcasts Stay Connected Subscribe - [Commissioned Analysis: Pharmaceutical Due Diligence Services](https://thewitfire.in/commissioned-analysis-pharmaceutical-due-diligence-services/) - Pharmaceutical due diligence services, CMC risk assessment and CRL readiness reviews. Fees from $900. Scope call free. Indian institutions quoted in rupees. - [Contact](https://thewitfire.in/contact/) - Contact — Witfire Elite (preview) Witfire Elite · Contact Four doors. Pick the one that matches what you are actually sending. Witfire Elite publishes pharma, biotech, healthcare, medical technology, CRO, diagnostic, hospital and life-science business analysis for a professional audience. Everything below reaches the editor directly. 01 · Routes Where to send what 1 You - [Dr. Akhilesh Vats—Editor-in-chief, Witfire Elite Pharma News](https://thewitfire.in/dr-akhilesh-vats-editor-the-witfire-elite-pharma-news/) - Dr. Akhilesh Vats, founder of ACME Research Solutions and editor at The Witfire, covers pharma intelligence, formulation science and biotech strategy. - [About Us](https://thewitfire.in/about-us/) - About Us The Witfire™ is a premium pharma intelligence platform for CEOs, founders, investors, and industry leaders. We cover pharmaceutical markets, innovation, leadership, startups, manufacturing, and business insights that matter to the future of healthcare.We are building a platform for those who lead and shape pharmaceutical research and formulation science in India. The Witfire is - [Advertising Policy](https://thewitfire.in/advertising-policy/) - The Witfire Elite Pharma News may accept advertising, sponsored articles, press releases, brand features, interviews, native advertising, media partnerships, and promotional content from pharma, biotech, healthcare, research, medical, startup, finance, and business-related organizations. - [Corrections Policy](https://thewitfire.in/corrections-policy/) - The Witfire Elite Pharma News aims to publish accurate, responsible, and useful pharma and healthcare industry coverage. - [Disclaimer](https://thewitfire.in/disclaimer/) - The Witfire Elite Pharma News publishes pharma news, healthcare business updates, biotech analysis, regulatory intelligence, market case studies, startup coverage, and sponsored content for informational and editorial purposes only. - [Terms & Conditions](https://thewitfire.in/terms-conditions/) - Welcome to The Witfire Elite Pharma News. By accessing or using this website, you agree to follow these Terms & Conditions. - [Privacy Policy](https://thewitfire.in/privacy-policy-2/) - The Witfire Elite Pharma News respects the privacy of its readers, contributors, advertisers, and visitors. This Privacy Policy explains how we collect, use, store, and protect information when you visit our website, read our articles, contact us, subscribe to updates, or interact with our content. - [Editorial Policy of The Witfire Elite Pharma News](https://thewitfire.in/editorial-policy/) - Read The Witfire Elite editorial policy for pharma news, regulatory intelligence, biotech analysis, healthcare business stories, startup coverage, investment insights, sponsored content, corrections, and editorial standards. ## Categories - [Pharma News](https://thewitfire.in/category/pharma-news/) - [Investments](https://thewitfire.in/category/investments/) - [Startups](https://thewitfire.in/category/startups/) - [Stock Market](https://thewitfire.in/category/stock-market/) - [Pharma Market Case Studies](https://thewitfire.in/category/pharma-news/pharma-market-case-studies/) - [FDA & Regulatory Intelligence](https://thewitfire.in/category/fda-regulatory-intelligence/) - [Philippines Pharma Watch](https://thewitfire.in/category/pharma-news/philippines-pharma-watch/) - [FDA & Regulatory Intelligence](https://thewitfire.in/category/pharma-news/fda-regulatory-intelligence-pharma-news/) - [Clinical Catalysts](https://thewitfire.in/category/pharma-news/clinical-catalysts/) ## Tags - [FDA & Regulatory Intelligence](https://thewitfire.in/tag/fda-regulatory-intelligence/) - [Case Studies](https://thewitfire.in/tag/case-studies/) - [IQVIA Signal](https://thewitfire.in/tag/iqvia-signal/) - [Lilly’s Germany](https://thewitfire.in/tag/lillys-germany/) - [Investment](https://thewitfire.in/tag/investment/) - [Germany Investment](https://thewitfire.in/tag/germany-investment/) - [Fulcrum’s Pociredir Collapse](https://thewitfire.in/tag/fulcrums-pociredir-collapse/) - [PRC2 Risk](https://thewitfire.in/tag/prc2-risk/) - [Sickle Cell Drug](https://thewitfire.in/tag/sickle-cell-drug/) - [FTX-6058](https://thewitfire.in/tag/ftx-6058/) - [Pociredir](https://thewitfire.in/tag/pociredir/) - [FTX-6058 and Pociredir](https://thewitfire.in/tag/ftx-6058-and-pociredir/) - [Tazverik Data](https://thewitfire.in/tag/tazverik-data/) - [Eli Lilly](https://thewitfire.in/tag/eli-lilly/) - [Retatrutide](https://thewitfire.in/tag/retatrutide/) - [ADA 2026](https://thewitfire.in/tag/ada-2026/) - [GLP-1](https://thewitfire.in/tag/glp-1/) - [generic Ozempic India](https://thewitfire.in/tag/generic-ozempic-india/) - [semaglutide price war](https://thewitfire.in/tag/semaglutide-price-war/) - [GLP-1 market India](https://thewitfire.in/tag/glp-1-market-india/) - [CagriSema](https://thewitfire.in/tag/cagrisema/) - [Novo Nordisk](https://thewitfire.in/tag/novo-nordisk/) - [Tirzepatide](https://thewitfire.in/tag/tirzepatide/) - [Wegovy](https://thewitfire.in/tag/wegovy/) - [Iran War Pharma Shock](https://thewitfire.in/tag/iran-war-pharma-shock/) - [China Biotech](https://thewitfire.in/tag/china-biotech/) - [API Dependence](https://thewitfire.in/tag/api-dependence/) - [Strait of Hormuz](https://thewitfire.in/tag/strait-of-hormuz/) - [India CRO Boom](https://thewitfire.in/tag/india-cro-boom/) - [China Biotech Licensing](https://thewitfire.in/tag/china-biotech-licensing/) - [Pharma Outsourcing](https://thewitfire.in/tag/pharma-outsourcing/) - [CDMO Strategy](https://thewitfire.in/tag/cdmo-strategy/) - [Biosecure Act](https://thewitfire.in/tag/biosecure-act/) - [Replimune](https://thewitfire.in/tag/replimune/) - [Vusolimogene Oderparepvec](https://thewitfire.in/tag/vusolimogene-oderparepvec/) - [Nivolumab](https://thewitfire.in/tag/nivolumab/) - [Advanced Melanoma](https://thewitfire.in/tag/advanced-melanoma/) - [FDA CRL](https://thewitfire.in/tag/fda-crl/) - [IGNYTE](https://thewitfire.in/tag/ignyte/) - [GSK](https://thewitfire.in/tag/gsk/) - [Zidesamtinib](https://thewitfire.in/tag/zidesamtinib/) - [NVL-520](https://thewitfire.in/tag/nvl-520/) - [Neladalkib](https://thewitfire.in/tag/neladalkib/) - [NVL-655](https://thewitfire.in/tag/nvl-655/) - [ROS1](https://thewitfire.in/tag/ros1/) - [NSCLC](https://thewitfire.in/tag/nsclc/) - [Lung Cancer](https://thewitfire.in/tag/lung-cancer/) - [B7-H3 ADC](https://thewitfire.in/tag/b7-h3-adc/) - [Moderna](https://thewitfire.in/tag/moderna/) - [mFlusiva](https://thewitfire.in/tag/mflusiva/) - [mRNA-1010](https://thewitfire.in/tag/mrna-1010/) - [FDA Refusal-to-File](https://thewitfire.in/tag/fda-refusal-to-file/) - [Influenza Vaccine](https://thewitfire.in/tag/influenza-vaccine/) - [Regulatory Risk](https://thewitfire.in/tag/regulatory-risk/) - [mRNA Technology](https://thewitfire.in/tag/mrna-technology/) - [Biotech Regulation](https://thewitfire.in/tag/biotech-regulation/) - [Revolution Medicines](https://thewitfire.in/tag/revolution-medicines/) - [Daraxonrasib](https://thewitfire.in/tag/daraxonrasib/) - [RASolute 302](https://thewitfire.in/tag/rasolute-302/) - [Pancreatic Cancer](https://thewitfire.in/tag/pancreatic-cancer/) - [Royalty Pharma](https://thewitfire.in/tag/royalty-pharma/) - [Oncology M&A](https://thewitfire.in/tag/oncology-ma/) - [Phase 3 Data](https://thewitfire.in/tag/phase-3-data/) - [Tanabe Pharma](https://thewitfire.in/tag/tanabe-pharma/) - [Uplizna](https://thewitfire.in/tag/uplizna/) - [Inebilizumab](https://thewitfire.in/tag/inebilizumab/) - [Zenas BioPharma](https://thewitfire.in/tag/zenas-biopharma/) - [Obexelimab](https://thewitfire.in/tag/obexelimab/) - [Bristol Myers Squibb](https://thewitfire.in/tag/bristol-myers-squibb/) - [IgG4-Related Disease](https://thewitfire.in/tag/igg4-related-disease/) - [Japan Pharma](https://thewitfire.in/tag/japan-pharma/) - [4SigHT](https://thewitfire.in/tag/4sight/) - [Sobi](https://thewitfire.in/tag/sobi/) - [Pegadricase](https://thewitfire.in/tag/pegadricase/) - [Viridian Therapeutic](https://thewitfire.in/tag/viridian-therapeutic/) - [Veligrotug-vvze](https://thewitfire.in/tag/veligrotug-vvze/) - [Tepezza](https://thewitfire.in/tag/tepezza/) - [Amgen](https://thewitfire.in/tag/amgen/) - [FDA Approval](https://thewitfire.in/tag/fda-approval/) - [Alzheimer’s Disease](https://thewitfire.in/tag/alzheimers-disease/) - [QuantumCell ApS](https://thewitfire.in/tag/quantumcell-aps/) - [NeuroRestore](https://thewitfire.in/tag/neurorestore/) - [AlzeCure Pharma](https://thewitfire.in/tag/alzecure-pharma/) - [ACD856](https://thewitfire.in/tag/acd856/) - [CNS Drug Development](https://thewitfire.in/tag/cns-drug-development/) - [Phase 1b](https://thewitfire.in/tag/phase-1b/) - [BDNF](https://thewitfire.in/tag/bdnf/) - [NGF](https://thewitfire.in/tag/ngf/) - [Trk-PAM](https://thewitfire.in/tag/trk-pam/) - [Phase 2](https://thewitfire.in/tag/phase-2/) - [Alzheimer’s Therapeutics](https://thewitfire.in/tag/alzheimers-therapeutics/) - [Out-Licensing](https://thewitfire.in/tag/out-licensing/) - [Neurotrophic Signaling](https://thewitfire.in/tag/neurotrophic-signaling/) - [European Biotech](https://thewitfire.in/tag/european-biotech/) - [Biotech Deal](https://thewitfire.in/tag/biotech-deal/) - [Nordic Biotech](https://thewitfire.in/tag/nordic-biotech/) - [Pharma Intelligence](https://thewitfire.in/tag/pharma-intelligence/) - [CMC](https://thewitfire.in/tag/cmc/) - [Achieve Life Sciences](https://thewitfire.in/tag/achieve-life-sciences/) - [ACHV](https://thewitfire.in/tag/achv/) - [Cytisinicline](https://thewitfire.in/tag/cytisinicline/) - [Adare Pharma Solutions](https://thewitfire.in/tag/adare-pharma-solutions/) - [Nicotine Dependence](https://thewitfire.in/tag/nicotine-dependence/) - [Vaping Cessation](https://thewitfire.in/tag/vaping-cessation/) - [ORCA-3](https://thewitfire.in/tag/orca-3/) - [ORCA-2](https://thewitfire.in/tag/orca-2/) - [Complete Response Letter](https://thewitfire.in/tag/complete-response-letter/) - [Smoking Cessation](https://thewitfire.in/tag/smoking-cessation/) - [OAI](https://thewitfire.in/tag/oai/) - [Manufacturing Execution](https://thewitfire.in/tag/manufacturing-execution/) - [Biotech Valuation](https://thewitfire.in/tag/biotech-valuation/) - [Wainua](https://thewitfire.in/tag/wainua/) - [Eplontersen](https://thewitfire.in/tag/eplontersen/) - [Ionis Pharmaceuticals](https://thewitfire.in/tag/ionis-pharmaceuticals/) - [CARDIO-TTRansform](https://thewitfire.in/tag/cardio-ttransform/) - [ATTR-CM](https://thewitfire.in/tag/attr-cm/) - [AstraZeneca](https://thewitfire.in/tag/astrazeneca/) - [Antisense Oligonucleotide](https://thewitfire.in/tag/antisense-oligonucleotide/) - [Tafamidis](https://thewitfire.in/tag/tafamidis/) - [TTR Silencer](https://thewitfire.in/tag/ttr-silencer/) - [Transthyretin Amyloid Cardiomyopathy](https://thewitfire.in/tag/transthyretin-amyloid-cardiomyopathy/) - [Attruby](https://thewitfire.in/tag/attruby/) - [Phase 3 Trial](https://thewitfire.in/tag/phase-3-trial/) - [Vutrisiran](https://thewitfire.in/tag/vutrisiran/) - [Amvuttra](https://thewitfire.in/tag/amvuttra/) - [Acoramidis](https://thewitfire.in/tag/acoramidis/) - [Vyndaqel](https://thewitfire.in/tag/vyndaqel/) - [Cardiovascular Mortality](https://thewitfire.in/tag/cardiovascular-mortality/) - [Biotech Investing](https://thewitfire.in/tag/biotech-investing/) - [Trial Design](https://thewitfire.in/tag/trial-design/) - [oral PCSK9 inhibitor](https://thewitfire.in/tag/oral-pcsk9-inhibitor/) - [LIPFENDRA](https://thewitfire.in/tag/lipfendra/) - [enlicitide decanoate](https://thewitfire.in/tag/enlicitide-decanoate/) - [CORALreef Lipids](https://thewitfire.in/tag/coralreef-lipids/) - [LIPFENDRA price](https://thewitfire.in/tag/lipfendra-price/) - [PCSK9 inhibitor](https://thewitfire.in/tag/pcsk9-inhibitor/) - [enlicitide](https://thewitfire.in/tag/enlicitide/) - [MSD](https://thewitfire.in/tag/msd/) - [Merck](https://thewitfire.in/tag/merck/) - [CORALreef AddOn](https://thewitfire.in/tag/coralreef-addon/) - [Praluent](https://thewitfire.in/tag/praluent/) - [MK-0616](https://thewitfire.in/tag/mk-0616/) - [CORALreef Outcomes](https://thewitfire.in/tag/coralreef-outcomes/) - [CORALreef HeFH](https://thewitfire.in/tag/coralreef-hefh/) - [AmgenNow](https://thewitfire.in/tag/amgennow/) - [evolocumab](https://thewitfire.in/tag/evolocumab/) - [Repatha](https://thewitfire.in/tag/repatha/) - [biosimilars](https://thewitfire.in/tag/biosimilars/) - [Talc Litigation](https://thewitfire.in/tag/talc-litigation/) - [Product Liability](https://thewitfire.in/tag/product-liability/) - [Johnson & Johnson](https://thewitfire.in/tag/johnson-johnson/) - [Pharma Legal Risk](https://thewitfire.in/tag/pharma-legal-risk/) - [Ovarian Cancer](https://thewitfire.in/tag/ovarian-cancer/) - [Mass Tort](https://thewitfire.in/tag/mass-tort/) - [Asbestos](https://thewitfire.in/tag/asbestos/) - [Teva](https://thewitfire.in/tag/teva/) - [pharma earnings](https://thewitfire.in/tag/pharma-earnings/) - [AUSTEDO](https://thewitfire.in/tag/austedo/) - [generic drugs](https://thewitfire.in/tag/generic-drugs/) - [ecopipam](https://thewitfire.in/tag/ecopipam/) - [AJOVY](https://thewitfire.in/tag/ajovy/) - [pulmonary artery denervation](https://thewitfire.in/tag/pulmonary-artery-denervation/) - [PULSE-LHD first U.S. patients](https://thewitfire.in/tag/pulse-lhd-first-u-s-patients/) - [NCT07214376](https://thewitfire.in/tag/nct07214376/) - [heart failure clinical trial](https://thewitfire.in/tag/heart-failure-clinical-trial/) - [PULSE-LHD trial](https://thewitfire.in/tag/pulse-lhd-trial/) - [CpcPH-LHD](https://thewitfire.in/tag/cpcph-lhd/) - [Henry Ford Hospital](https://thewitfire.in/tag/henry-ford-hospital/) - [FDA IDE](https://thewitfire.in/tag/fda-ide/) - [Enhancor System](https://thewitfire.in/tag/enhancor-system/) - [Pulnovo Medical](https://thewitfire.in/tag/pulnovo-medical/) - [PADN](https://thewitfire.in/tag/padn/) - [CMS G250159](https://thewitfire.in/tag/cms-g250159/) - [HARBOR-AF trial](https://thewitfire.in/tag/harbor-af-trial/) - [NCT07792239](https://thewitfire.in/tag/nct07792239/) - [CLN-209](https://thewitfire.in/tag/cln-209/) - [AF burden](https://thewitfire.in/tag/af-burden/) - [budiodarone](https://thewitfire.in/tag/budiodarone/) - [antiarrhythmic drugs](https://thewitfire.in/tag/antiarrhythmic-drugs/) - [wearable cardiac monitoring](https://thewitfire.in/tag/wearable-cardiac-monitoring/) - [persistent atrial fibrillation](https://thewitfire.in/tag/persistent-atrial-fibrillation/) - [paroxysmal atrial fibrillation](https://thewitfire.in/tag/paroxysmal-atrial-fibrillation/) - [LEAF](https://thewitfire.in/tag/leaf/) - [atrial fibrillation](https://thewitfire.in/tag/atrial-fibrillation/) - [XYRA](https://thewitfire.in/tag/xyra/) - [FDA Advisory 2026-1007](https://thewitfire.in/tag/fda-advisory-2026-1007/) - [Philippine FDA](https://thewitfire.in/tag/philippine-fda/) - [medical device regulation](https://thewitfire.in/tag/medical-device-regulation/) - [public bidding](https://thewitfire.in/tag/public-bidding/) - [RA 9711](https://thewitfire.in/tag/ra-9711/) - [customs clearance](https://thewitfire.in/tag/customs-clearance/) - [CPR renewal](https://thewitfire.in/tag/cpr-renewal/) - [CDRRHR](https://thewitfire.in/tag/cdrrhr/) - [product registration](https://thewitfire.in/tag/product-registration/) - [procurement](https://thewitfire.in/tag/procurement/) - [Philippines Pharma Watch](https://thewitfire.in/tag/philippines-pharma-watch/) - [Alevia-B composition](https://thewitfire.in/tag/alevia-b-composition/) - [Philippines pharma](https://thewitfire.in/tag/philippines-pharma/) - [pyridoxine hydrochloride](https://thewitfire.in/tag/pyridoxine-hydrochloride/) - [PascualLab](https://thewitfire.in/tag/pascuallab/) - [Alevia-B Philippines](https://thewitfire.in/tag/alevia-b-philippines/) - [Alevia-B](https://thewitfire.in/tag/alevia-b/) - [Alevia-B FDA Philippines](https://thewitfire.in/tag/alevia-b-fda-philippines/) - [paracetamol B1 B6 B12](https://thewitfire.in/tag/paracetamol-b1-b6-b12/) - [OTC medicines Philippines](https://thewitfire.in/tag/otc-medicines-philippines/) - [Pascual Consumer Healthcare](https://thewitfire.in/tag/pascual-consumer-healthcare/) - [PascualLab Alevia-B](https://thewitfire.in/tag/pascuallab-alevia-b/) - [Lloyd Laboratories](https://thewitfire.in/tag/lloyd-laboratories/) - [nerve-related pain](https://thewitfire.in/tag/nerve-related-pain/) - [RENGEVITY-201 Phase 2](https://thewitfire.in/tag/rengevity-201-phase-2/) - [RENGEVITY-201 trial](https://thewitfire.in/tag/rengevity-201-trial/) - [Veloxis Pharmaceuticals](https://thewitfire.in/tag/veloxis-pharmaceuticals/) - [organ rejection](https://thewitfire.in/tag/organ-rejection/) - [CD28 blockade](https://thewitfire.in/tag/cd28-blockade/) - [VEL-101](https://thewitfire.in/tag/vel-101/) - [calcineurin inhibitor](https://thewitfire.in/tag/calcineurin-inhibitor/) - [pegrizeprument](https://thewitfire.in/tag/pegrizeprument/) - [kidney transplantation](https://thewitfire.in/tag/kidney-transplantation/) - [tacrolimus](https://thewitfire.in/tag/tacrolimus/) - [FR104](https://thewitfire.in/tag/fr104/) - [NCT0729077](https://thewitfire.in/tag/nct0729077/)